Factor Eight Inhibitor Bypassing Activity

Production of Plasma Proteins for Therapeutic Use

Volumn , Issue , 2012, Pages 49-63

  Turecek, Peter ^a   Schwarz, Hans Peter ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

APTT, FVIII inhibitor clotting; FEIBA efficacy safety; FVIII inhibitor bypassing; Prothrombin and Factor Xa; Prothrombin complex zymogen

Indexed keywords

EID: 84886160786     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118356807.ch4     Document Type: Chapter

References (103)

1. Sultan Y, Algiman M. (1990) Treatment of factor VIII inhibitors. Blood Coagul Fibrinolysis, 1, 193-199.
2. Macik BG. (1993) Treatment of factor VIII Inhibitors, products and strategies. Semin Thromb Hemost, 19, 13-24.
3. Breen FA, Jr., Tullis JL. (1969) Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA, 208, 1848-1852.
4. DeWitt RT, Feinstein DI. (1977) Prothrombin complex concentrate. Arch Intern Med, 137, 1211-1213.
5. Kurczynski EM, Penner JA. (1974) Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med, 291, 164-167.
6. Sultan Y, Brouet JC, Debre P. (1974) Letter: treatment of inhibitors to factor VIII with activated prothrombin concentrate. N Engl J Med, 291, 1087.
7. Kelly P, Penner JA. (1976) Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA, 236, 2061-2064.
8. Fekete LF, Holst SL, Peetoom F, De Veber LI. (1972) "Auto" factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. Abstract 295. International Congress of Hematology, Sao Paulo, 1972.
9. Elsinger F. (1975) Shortening of clotting times of hemophilia A plasma with inhibitors induced by activated factor IX concentrates (Fraction FEIBA) (Oral presentation). ICTH Task Force Meeting "Clinical use of FIX concentrates", Paris, 1975.
10. Elsinger F. (1976) Zum Wirkungsmechanismus von Fraktion FEIBA, Landbeck G, Marx R, 6th Hamophilie Symposium, Hamburg, 1975, Immuno GmbH Heidelberg, pp. 91-94.
11. Prowse CV. (1982) Activated prothrombin complex concentrates, approaches to their preparation. Thromb Res, 25, 213-218.
12. Berting A, Modrof J, Unger U, Gessner M, Klotz A, Poelsler G, Kreil TR. (2008) Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates. Transfusion, 48, 1220-1226.
13. Vinazzer H. (1982) Comparison between two concentrates with factor VIII inhibitor bypassing activity. Thromb Res, 26, 21-29.
14. Ehrlich HJ, Henzl MJ, Gomperts ED. (2002) Safety of factor VIII inhibitor bypass activity (FEIBA), 10-year compilation of thrombotic adverse events. Haemophilia, 8, 83-90.
15. Barrowcliffe TW, Kemball-Cook G, Gray E. (1981) Factor VIII inhibitor bypassing activity: a suggested mechanism of action. Thromb Res, 21, 181-186.
16. MunteanW. (1984) Purified complex of factor VIII coagulant moiety and phospholipid, high factor VIII coagulant activity in factor VIII inhibitor plasma. Wien Klin Wochenschr, 96, 829-832.
17. Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG. (1982) The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (factor IX) concentrates in rabbits. Blood, 59, 401-407.
18. Lundblad RL, Bergstrom J, De Vreker R, Bray G, Gomperts E, Baker D, Kingdon HS, Mann KG, Hartshorn J, Jenny RJ. (1998) Measurement of active coagulation factors in Autoplex-T with colorimetric active site-specific assay technology. Thromb Haemost, 80, 811-815.
19. Wilms K, Sander W. (1990) Activated prothrombin complex preparations for the treatment of anticoagulant hemophilia. Preparation-method of operation-supply possibility. Folia Haematol Int Mag Klin Morphol Blutforsch, 117, 589-593.
20. SanderW, Wilms K. (1990) Contribution to the mechanism of the "factor VIII bypassing activity" (FEIBA)-reaction. Folia Haematol Int Mag Klin Morphol Blutforsch, 117, 581-587.
21. Turecek PL, Varadi K, Gritsch H, AuerW, Pichler L, Eder G, Schwarz HP. (1999) Factor Xa and prothrombin, mechanism of action of FEIBA. Vox Sang, 77, 72-79.
22. Lowe GD, Harvie A, Forbes CD, Prentice CR. (1976) Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor. Br Med J, 2, 1110-1111.
23. Kagawa H, Yasuzawa M, Ozaki Y, Yamamoto Y, Katsurada T, Nomura S, Okubo S, Fukuhara S. (1996) The effect of nonactivated prothrombin complex concentrate (Proplex ST) on intraperitoneal hematoma in a hemophilia A patient with a factor VIII inhibitor. Intern Med, 35, 319-322.
24. Teitel JM, Ni HY, Freedman JJ, Garvey MB. (1988) The endothelial cell and the factor VIII bypassing activity of prothrombin complex concentrate. Thromb Haemost, 60, 226-229.
25. Leissinger CA. (1999) Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitors. Haemophilia, 5, 25-32.
26. Niiya K, Hirose S, Taguchi H, Miyoshi I. (1985) Nonactivated and activated prothrombin complex concentrates, Proplex and FEIBA, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX. Rinsho Ketsueki, 26, 980-984.
27. HilgartnerMW, Knatterud GL. (1983) The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood, 61, 36-40.
28. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ. (1981) The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med, 305, 717-721.
29. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. (1980) Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII, a multicenter therapeutic trial. N Engl J Med, 303, 421-425.
30. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier AI, Whitehurst DA. (1983) Autoplex versus Proplex, a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood, 62, 1135-1138.
31. Gomperts ED, Fannon RB, Lee ML, Kingdon HS, Kantrowitz JL, Addiego JE, Jr., Carney J, Corrigan JJ, Hathaway W, Hilgartner MW, et al. (1986) PROPLEX vs. PROPLEX SX, a controlled double blind study of the effectiveness in treating acute hemarthroses in hemophilia A patients with inhibitors to factor VIII. Thromb Res, 42, 789-796.
32. Menache D, Roberts HR. (1975) Summary report and recommendations of the task force members and consultants. Thrombos Diathes Haemorrh, 33, 645-647.
33. Hellstern P. (1999) Production and composition of prothrombin complex concentrates, correlation between composition and therapeutic efficiency. Thromb Res, 95, S7-S12.
34. Kohler M, Heiden M, Harbauer G, Miyashita C, Morsdorf S, Braun B, Ernert P, Wenzel E, Rose S, Pindur G. (1990) Comparison of different prothrombin complex concentrates- in vitro and in vivo studies. Thromb Res, 60, 63-70.
35. Kohler M, Hellstern P, Lechler E, Überfuhr P, Muller-Berghaus G. (1998) Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost, 80, 399-402.
36. Estry DW, Tishkoff GH. (1984) Apparent intrinsic prothrombinase activity of human factor X zymogen, identification with factor VIII inhibitor bypassing activity (FEIBA). Thromb Res, 36, 549-562.
37. McLaughlin LF, Drummond O, MacGregor IR. (1992) A novel rat model of thrombogenicity, its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates. Thromb Haemost, 68, 511-515.
38. MacGregor IR, Ferguson JM, McLaughlin LF, Burnouf T, Prowse CV. (1991) Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity. Thromb Haemost, 66, 609-613.
39. Thomas DP, Hampton KK, Dasani H, Lee CA, Giangrande PL, Harman C, Lee ML, Preston FE. (1994) A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol, 87, 782-788.
40. Hampton KK, Preston FE, Lowe GD, Walker ID, Sampson B. (1993) Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate. Br J Haematol, 84, 279-284.
41. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Santagostino E, Tradati FC, Rosenberg RD. (1991) No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate. Br J Haematol, 79, 606-611.
42. Mannucci PM, Bauer KA, Gringeri A, Barzegar S, Bottasso B, Simoni L, Rosenberg RD. (1990) Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. Blood, 76, 2540-2545.
43. Gallistl S, Cvirn G, Leschnik B, Muntean W. (2002) Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrinolysis, 13, 653-655.
44. Sultan Y, Loyer F. (1993) In vitro evaluation of factor VIIIbypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors, thrombin generation test in the presence of collagen-activated platelets. J Lab Clin Med, 121, 444-452.
45. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP. (2003) Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb, 33, 16-22.
46. Varadi K, Negrier C, Berntorp E, Astermark J, Bordet J-C, Morfini M, Linari S, Schwarz HP, Turecek PL. (2003) Monitoring the bioavailability of FEIBA with a Thrombin generation assay. J Thromb Haemost, 1, 2374-2380.
47. Himmelspach M, Richter G, Muhr E, Varadi K, Turecek PL, Dorner F, Schwarz HP, Schlokat U. (2002) A fully recombinant partial prothrombin complex effectively bypasses FVIII in vitro and in vivo. Thromb Haemost, 88, 1003-1011.
48. Richter G, Schwarz HP, Dorner F, Turecek PL. (2002) Activation and inactivation of human factor X by proteases derived from Ficus carica. Br J Haematol, 119, 1042-1051.
49. Giles AR, Tinlin S, Greenwood R. (1982) A canine model of hemophilic (factor VIII, C deficiency) bleeding. Blood, 60, 727-730.
50. Giles AR, Tinlin S, Hoogendoorn H, Fournel MA, Ng P, Pancham N. (1988) In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency). Blood, 72, 335-339.
51. Kingdon HS, Hassell TM. (1981) Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions. Blood, 58, 868-872.
52. Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. (1984) Development of factor VIII, C antibodies in dogs with hemophilia A (factor VIII, C deficiency). Blood, 63, 451-456.
53. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. (1989) Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci USA, 86, 1382-1386.
54. Mertens K, Briet E, Giles AR. (1990) The role of factor VII in haemostasis, infusion studies of factor VIIa in a canine model of factor VIII deficiency. Thromb Haemost, 64, 138-144.
55. Giles AR, Mann KG, Nesheim ME. (1988) A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol, 69, 491-497.
56. Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP. (1997) Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost, 77, 591-599.
57. Patthy L. (1990) Evolution of blood coagulation and fibrinolysis. Blood Coagul Fibrinolysis, 1, 153-166.
58. Doolittle RF. (1993) The evolution of vertebrate blood coagulation, a case of Yin and Yang. Thromb Haemost, 70, 24-28.
59. Karges HE, Funk KA, Ronneberger H. (1994) Activity of coagulation and fibrinolysis parameters in animals. Arzneimittelforschung, 44, 793-797.
60. Kristensen AT, Madsen MT, Nielsen GN, Ezban M. (1999) Recombinant human FVIIa dose dependently shortens the bleeding time in a rabbit model of antibody induced hemophilia A. Thromb Haemost (Suppl), 328 (Abs. No. 1038).
61. Shapiro A. (2001) Inhibitor treatment, state of the art. Semin Hematol, 38 (Suppl. 12), 26-34.
62. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. (2003) A new approach to treatment of bleeding episodes in young hemophilia patients, a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost, 1, 450-455.
63. Jeroukhimov I, Jewelewicz D, Zaias J, Hensley G, MacLeod J, Cohn SM, Rashid Q, Pernas F, Ledford MR, Gomez-Fein E, Lynn M. (2002) Early injection of high-dose recombinant factor VIIa decreases blood loss and prolongs time from injury to death in experimental liver injury. J Trauma, 53, 1053-1057.
64. Hoffman M, Monroe DM 3rd. (2003) The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon, 49, 14-21.
65. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, Messina M, Mannucci PM. (2005) Environmental risk factors for inhibitor development in children with haemophilia A, a case-control study. Br J Haematol, 130, 422-427.
66. Oldenburg J, Pavlova A. (2006) Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia, 12 Suppl. 6, 15-22.
67. Gouw SC, van der Bom JG, Marijke van den BH. (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A, the CANAL cohort study. Blood, 109, 4648-4654.
68. Ehrlich HJ, Bray GL, Gomperts ED. (1998) Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A. Thromb Haemost, 79, 242-243.
69. KreuzW, Ettingshausen CE, Zyschka A, Oldenburg J, Saguer IM, Ehrenforth S, Klingebiel T. (2002) Inhibitor development in previously untreated patients with hemophilia A, a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost, 28, 285-290.
70. Hay CR. (1998) Factor VIII inhibitors in mild and moderateseverity haemophilia A. Haemophilia, 4, 558-563.
71. Ehrenforth S, KreuzW, Scharrer I, Linde R, Funk M, Güngor T, Krackhardt B, Kornhuber B. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594-598.
72. Scharrer I, Bray GL, Neutzling O. (1999) Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Hemophilia, 5, 145-154.
73. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Gungor T, Kornhuber B. (1996) Epidemiology of inhibitors in haemophilia A. Vox Sang, 70 (Suppl. 1), 2-8.
74. Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. (2003) Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost, 1, 2548-2553.
75. Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, Poletti A, Girolami A. (1996) High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients, a possible role for the half-life of transfused FVIII. Br J Haematol, 93, 688-693.
76. Vianello F, Radossi P, Tison T, Dazzi F, Tagariello G, Davoli PG, Girolami A. (1997) Prevalence of anti-FVIII antibodies in severe haemophilia A patients with inversion of intron 22. Br J Haematol, 97, 807-809.
77. Negrier C, Roblet S, Koppers K, Bagot d'Arc M, Calvora R. (2001) Multicentre prospective survey on the use of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost, 86 (Suppl.), P2543.
78. Negrier C, Rossi F, Bagot d'Arc M, the members of the French FEIBA study group. (1999) Multicenter prospective survey on the use of FEIBA in France in patients with factor VIII and factor IX inhibitors [abstract 1923D]. XVII Congress of the International Society on Thrombosis and Haemostasis, Washington, DC, USA, 1999.
79. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. (1997) Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor eight bypassing activity. Thromb Haemost, 77, 1113-1119.
80. Mizon P, Goudemand J, Jude B, Marey A. (1992) Myocardial infarction after FEIBA therapy in a haemophilia-B patient with factor IX inhibitor. Ann Hematol, 64, 309-311.
81. Rivard GE, Vick S, David M. (1993) The use of factor VIII inhibitor by-passing activity (FEIBA, Immuno) and porcine factor VIII (Hyate, C, Porton) for treatment of patients with inhibitors: the Canadian experience, 1988-1993 [abstract]. Second International Symposium on Inhibitors to Coagulation Factors, University of North Carolina at Chapel Hill, 1993.
82. Hilgartner M, Aledort L, Andes A, Gill J. (1990) Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion, 30, 626-630.
83. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group. (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor, the FEIBA Novo-Seven Comparative (FENOC) Study. Blood, 109, 546-551.
84. DiMichele D, Negrier C. (2006) A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia, 12, 352-362.
85. National Hemophilia Foundation, Medical and Scientific Advisory Council (MASAC). (2006) Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). Document #170 (Replaces #117), National Hemophilia Foundation, New York, NY. www.hemophilia.org/NHFWeb/Resource/Static-Pages/menu0/menu5/menu57/170.pdf. Accessed December 1, 2011.
86. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med, 357, 535-544.
87. Valentino LA. (2006) FEIBA Prophylaxis for patients with haemophilia and inhibitors. Haemophilia, 12 (Suppl. 5), 26-31.
88. Leissinger CA, Becton DL, Ewing NP, Valentino LA. (2007) Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia, 13, 249-255.
89. Hilgartner MW, Makipernaa A, DiMichele DM. (2003) Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia, 9, 261-268.
90. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, et al. (2011) Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med, 365, 1684-1692.
91. Ewing N, De Guzman C, Pullens L. (2007) Anamnesis in patients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis [abstract]. J Thromb Haemost, 5 (Suppl. 2) P-T-158.
92. Mann KG, Brummel K, Butenas S. (2003) What is all that thrombin for?. J Thromb Haemost, 1, 1504-1514.
93. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. (1996) A common genetic variation in the 30-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88, 3698-3703.
94. Billy D, Willems GM, Hemker HC, Lindhout T. (1995) Prothrombin contributes to the assembly of the factor Va-factor Xa complex at phosphatidylserine-containing phospholipid membranes. J Biol Chem, 270, 26883-26889.
95. Brufatto N, Ward A, Nesheim ME. (2003) Factor Xa is highly protected from antithrombin-fondaparinux and antithrombinenoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost, 1, 1258-1263.
96. Liu L, Zhang Q, Spencer F, Chung E, Furman M, Gore J, Becker R. (1996) Persistent survival of platelet factor Va activity in plasma. Blood, 88 (Suppl. 1), 526a.
97. Baglia FA, Walsh PN. (1996) Prothrombin mediates the binding of factor XI to human platelets and its activation by thrombin. Blood, 88 (Suppl. 1), 520a (abstract 2069).
98. Baglia FA, Walsh PN. (1998) Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for plateletmediated factor XI activation by thrombin. Biochemistry, 37, 2271-2281.
99. London FS, Walsh PN. (2000) Zymogen factor IX potentiates factor IXa-catalyzed factor X activation. Biochemistry, 39, 9850-9858.
100. Wildgoose P, KisielW. (1989) Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. Blood, 73, 1888-1895.
101. Zwaal RF, Comfurius P, Bevers EM. (1992) Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta, 1180, 1-8.
102. Hoffman M, Monroe DM. (2001) A cell-based model of hemostasis. Thromb Haemost, 85, 958-965.
103. Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. (1979) Activation of human factor VII in plasma and in purified systems, roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest, 64, 1056-1065.